Table 1.
Neuropsychiatric Symptoms in 14 Interferon Alfa–Treated Patients With HCV Compared With 14 Untreated Controls With HCV
| Symptom Dimension | Scale Score, Mean (SD)
|
P Value | |
|---|---|---|---|
| Control Group | Interferon Alfa–Treated Group | ||
| Depression (MADRS) | 3.4 (3.1) | 11.1 (9.6) | <.01 |
| Anhedonia (SHAPS) | 2.6 (3.2) | 9.6 (8.1) | <.01 |
| Fatigue (MFI)a | |||
| General fatigue | 9.1 (4.7) | 11.6 (5.5) | .22 |
| Physical fatigue | 8.8 (2.7) | 10.4 (5.2) | .32 |
| Reduced activity | 7.8 (2.6) | 9.4 (3.6) | .21 |
| Reduced motivation | 7.2 (2.4) | 9.1 (3.9) | .16 |
| Mental fatigue | 8.3 (3.4) | 9.6 (4.1) | .40 |
| Neurotoxicity (NRS) | |||
| Sickness symptoms | 3.8 (3.3) | 6.3 (3.8) | .08 |
| Cognitive symptoms | 2.1 (2.2) | 2.8 (2.6) | .41 |
| Motor symptoms | 0.7 (1.3) | 1.1 (1.5) | .52 |
Abbreviations: HCV, hepatitis C virus; MADRS, Montgomery-Asberg Depression Rating Scale; MFI, Multidimensional Fatigue Inventory; NRS, Neurotoxicity Rating Scale; SHAPS, Snaith-Hamilton Pleasure Scale.
a
Data for the MFI scale were missing for 1 untreated patient with HCV.